Page 173 - Assessing right ventricular function and the pulmonary circulation in pulmonary hypertension Onno Anthonius Spruijt

subjects, while no difference was seen in RV-A coupling (table 1). Final diagnosis and medication of control subjects are summarized in table 2.
Chapter 10
Characteristics
Age (years) Sex (n female) BSA (m2) Diagnosis
NYHA (II/III, n)
Treatment (n)
None
ERA
PDE5I Prostanoids ERA + PDE5I Ca antagonists B-blockers
CPET max
VO2/kg (ml/kg/min) Work (Watt)
HR (BPM)
RHC rest
HR (BPM)
CI (L/min)
mPAP (mmHg) PAWP (mmHg) PVR (dyne/s/cm5) mRAP (mmHg) SaO2 (%)
SvO2 (%)
CMRI
RVEDV (ml) RVESV (ml)
Control subjects (n=5)
38 (12)
3 1.853 (0.327)
PH (n=16)
57 (14)
11
1.883 (0.181) 12 IPAH; 1 HPAH 3 CTEPH
9 / 7
5 2 1 0 8 1 2
16 (5) 90 (44) 139 (15)
77 (15) 3.1 (0.6) 53 (8) 12 (2) 582 (168) 7 (4) 95 (2) 70 (4)
151 (52) 88 (53)
P-value
0.015 0.717 0.850
31 (8) 187 (87) 174 (5)
75 (14) 4.7 (0.8) 18 (2) 11 (2) 69 (14) 4 (1) 99 (0.5) 82 (2)
- -
<0.001 0.005 <0.001
0.785 <0.001 <0.001 0.475 <0.001 0.015 <0.001 <0.001
171
10